Ypsomed reaches agreement in legal dispute with Insulet

Press Releases Ypsomed Group

Burgdorf – Ypsomed (SWX: YPSN) has reached an agreement in its legal dispute with Insulet Corp. (NASDAQ: PODD). Insulet acknowledges the contractually agreed fee and compensates Ypsomed for the termination of the cooperation with an additional USD 36.15 million. The total compensation thus amounts to USD 41.25 million. At the same time, Insulet drops its counterclaim of USD 18.7 million.

Read more...

Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes

Burgdorf / Indianapolis – Eli Lilly and Company (NYSE: LLY) and Ypsomed (SWX: YPSN) announced today a non-exclusive, global agreement to advance an automated insulin delivery system as part of Lilly’s connected diabetes solutions. Under the terms of the agreement, Lilly will commercialize the system, which is currently in development and will include an insulin pump developed and manufactured by Ypsomed.

Read more...

Burgdorf / Mainz / Basel – Ypsomed advances its patch injector into a comprehensive solution by entering into a collaboration with SCHOTT, one of the leading suppliers of pharmaceutical primary packaging, and Lonza, a leading global partner of the pharmaceutical and biotechnology industry for the development, manufacturing and testing of pharmaceuticals. In a joint effort, the three companies are developing a comprehensive solution for wearable patch injectors for the subcutaneous self-injection of large volumes of liquid formulations. This solution should enable pharmaceutical companies to quickly bring biopharmaceuticals in a patch injector into the clinical trial stage and to the market. For patients, the solution reduces the number of hospital visits required for treatment.

Read more...

Ypsomed grows and creates 102 new jobs

Press Releases Ypsomed Group

Burgdorf – Ypsomed (SWX: YPSN) increased sales by 4.6% or CHF 8.7 million in the first six months of 2020/21 compared to the previous year, and generated an operating profit (EBIT) of CHF 8.3 million. The company continued on its growth course in a challenging environment, driving forward all strategic initiatives and creating 102 new jobs at the same time.

Read more...